FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186704625> ?p ?o ?g. }

• W3186704625 endingPage "331" @default.
• W3186704625 startingPage "330" @default.
• W3186704625 abstract "We would like to express our gratitude for the readers’ interest in our published article entitled “Pneumonia in medical professionals during COVID-19 outbreak in cardiovascular hospital” published in the International Journal of Infectious Diseases (Ilic et al., 2021Ilic I Zdravkovic M Timcic S Stojanovic DU Bojic M Loncar G. Pneumonia in medical professionals during COVID-19 outbreak in cardiovascular hospital.Int J Infect Dis. 2021; 103: 188-193https://doi.org/10.1016/j.ijid.2020.11.156Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar). In the study it was found that medical professionals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who had been immunized against seasonal influenza had a lower incidence of computed tomography-confirmed bilateral pneumonia. We sought to explain this by presenting evidence of structural similarities between the Coronaviridae (SARS-CoV-2) and Orthomyxoviridae (influenza virus) families in the structural glycoprotein named haemagglutinin esterase (HE), which was shared by lateral gene transfer around 8000 years ago. These similarities could lead to cross-reactivity and enhanced immunity against SARS-CoV-2 in persons who have previously received the seasonal influenza vaccine (Ilic et al., 2021Ilic I Zdravkovic M Timcic S Stojanovic DU Bojic M Loncar G. Pneumonia in medical professionals during COVID-19 outbreak in cardiovascular hospital.Int J Infect Dis. 2021; 103: 188-193https://doi.org/10.1016/j.ijid.2020.11.156Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar). Zandi and colleagues have questioned this by stating that SARS-CoV-2 does not have a distinctive HE glycoprotein and thus cross-reactivity could not be the reason for the enhanced immunity against SARS-CoV-2 in persons vaccinated against influenza. However, this statement is only partially true. SARS-CoV-2, like other Coronaviridae, has a similar structure consisting of spike (S) protein, membrane (M) protein, envelope (E) protein, and nucleocapsid (N) protein. Although not identified as a distinct protein in SARS-CoV-2, HE has been identified previously in the Betacoronavirus family as a part of the S1 domain that helps viral attachment to the surface of the host cell using sialic acid on the host cell's glycoproteins, while HE within the S1 domain exhibits sialate O-acetylesterase receptor destroying activity (Huang et al., 2015Huang X Dong W Milewska A Golda A Qi Y et al.Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme.J Virol. 2015; 89: 7202-7213https://doi.org/10.1128/JVI.00854-15Crossref PubMed Scopus (174) Google Scholar). Evolutionary adaptation to the sialoglycome of the human respiratory tract has led to a loss of HE receptor-binding activity and a reduction in virion-associated esterase activity (Bakkers et al., 2017Bakkers MJ Lang Y Feitsma LJ Hulswit RJ de Poot SA et al.Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity.Cell Host Microbe. 2017; 21: 356-366https://doi.org/10.1016/j.chom.2017.02.008Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar). However, the S glycoprotein of SARS-CoV-2 has retained properties regarding host receptor binding that are common for Coronaviridae and influenza virus group C and D, indicating conserved recognizing structures. Comparative protein sequence analysis showed that the short region of the novel coronavirus S2 subunit that undergoes conformational changes to attach to host cells resembles the structure of influenza H3N2 haemagglutinin. Although the S protein of the novel coronavirus differs from the binding proteins of influenza virus, there is evidence that antiviral drugs that were used to treat influenza have activity against SARS-CoV-2. A small study explored the potential effects of umifenovir, a drug registered for influenza treatment, on SARS-CoV-2, by comparing structural similarities between SARS-CoV-2 and influenza H3N2 trimerization domains involved in drug binding. When superimposed, the binding regions for the drug of both viral species demonstrated significant structural similarities (Vankadari and Wilce, 2020Vankadari N Wilce JA Emerging Wuhan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26.Emerg Microb Infect. 2020; 9: 601-604https://doi.org/10.1080/22221751.2020.1739565Crossref PubMed Scopus (435) Google Scholar; Vankadari, 2020Vankadari N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.Int J Antimicrob Agents. 2020; 56105998https://doi.org/10.1016/j.ijantimicag.2020.105998Crossref PubMed Scopus (184) Google Scholara). Although evidence regarding the structure and function of the novel coronavirus is emerging, it must be noted that immunization itself is a process that stimulates the immune system of the vaccinated person, so that the response to another pathogen may be enhanced leading to the observed associations found in our study. Since COVID-19 is a multifaceted disease, the real impact of influenza immunization on the incidence and severity of the disease can only be explored in a large-scale retrospective study where other factors that have a proven influence on the severity of the disease, like diabetes, hypertension, and obesity, are well balanced between the study groups. Funding source: This research project was not sponsored or partially funded by any agency or company. Ethical approval: The manuscript has been approved by the Institutional Ethics Committee. Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper." @default.
• W3186704625 created "2021-08-02" @default.
• W3186704625 creator A5004355431 @default.
• W3186704625 creator A5017366194 @default.
• W3186704625 creator A5088280807 @default.
• W3186704625 date "2021-09-01" @default.
• W3186704625 modified "2023-10-18" @default.
• W3186704625 title "Influenza immunization and COVID-19—can viral structure be responsible for the effect?" @default.
• W3186704625 cites W1539248632 @default.
• W3186704625 cites W2593277929 @default.
• W3186704625 cites W3012088820 @default.
• W3186704625 cites W3018360824 @default.
• W3186704625 cites W3103845102 @default.
• W3186704625 doi "https://doi.org/10.1016/j.ijid.2021.07.055" @default.
• W3186704625 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8312082" @default.
• W3186704625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34325043" @default.
• W3186704625 hasPublicationYear "2021" @default.
• W3186704625 type Work @default.
• W3186704625 sameAs 3186704625 @default.
• W3186704625 citedByCount "0" @default.
• W3186704625 crossrefType "journal-article" @default.
• W3186704625 hasAuthorship W3186704625A5004355431 @default.
• W3186704625 hasAuthorship W3186704625A5017366194 @default.
• W3186704625 hasAuthorship W3186704625A5088280807 @default.
• W3186704625 hasBestOaLocation W31867046251 @default.
• W3186704625 hasConcept C116675565 @default.
• W3186704625 hasConcept C126322002 @default.
• W3186704625 hasConcept C159047783 @default.
• W3186704625 hasConcept C203014093 @default.
• W3186704625 hasConcept C2777914695 @default.
• W3186704625 hasConcept C2778158872 @default.
• W3186704625 hasConcept C2779134260 @default.
• W3186704625 hasConcept C3008058167 @default.
• W3186704625 hasConcept C524204448 @default.
• W3186704625 hasConcept C71924100 @default.
• W3186704625 hasConceptScore W3186704625C116675565 @default.
• W3186704625 hasConceptScore W3186704625C126322002 @default.
• W3186704625 hasConceptScore W3186704625C159047783 @default.
• W3186704625 hasConceptScore W3186704625C203014093 @default.
• W3186704625 hasConceptScore W3186704625C2777914695 @default.
• W3186704625 hasConceptScore W3186704625C2778158872 @default.
• W3186704625 hasConceptScore W3186704625C2779134260 @default.
• W3186704625 hasConceptScore W3186704625C3008058167 @default.
• W3186704625 hasConceptScore W3186704625C524204448 @default.
• W3186704625 hasConceptScore W3186704625C71924100 @default.
• W3186704625 hasLocation W31867046251 @default.
• W3186704625 hasLocation W31867046252 @default.
• W3186704625 hasLocation W31867046253 @default.
• W3186704625 hasOpenAccess W3186704625 @default.
• W3186704625 hasPrimaryLocation W31867046251 @default.
• W3186704625 hasRelatedWork W3008700721 @default.
• W3186704625 hasRelatedWork W3012050440 @default.
• W3186704625 hasRelatedWork W3022913415 @default.
• W3186704625 hasRelatedWork W3043885589 @default.
• W3186704625 hasRelatedWork W3094067199 @default.
• W3186704625 hasRelatedWork W3114196634 @default.
• W3186704625 hasRelatedWork W3166767160 @default.
• W3186704625 hasRelatedWork W3196971770 @default.
• W3186704625 hasRelatedWork W4200427971 @default.
• W3186704625 hasRelatedWork W4205735757 @default.
• W3186704625 hasVolume "110" @default.
• W3186704625 isParatext "false" @default.
• W3186704625 isRetracted "false" @default.
• W3186704625 magId "3186704625" @default.
• W3186704625 workType "article" @default.